PRAX logo

Praxis Precision Medicines Inc

PRAX

Build a strategy around PRAX

Accountable AI Logo

Praxis Precision Medicines Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-26

Snapshot

  • P/S ratio of 792x vs industry median 2.7x - valuation prices in blockbuster drug success with zero margin for error[P/S Ratio]
  • Cash burn of 229M TTM against 150M cash leaves ~8 months runway without new financing[Free Cash Flow TTM]
  • R&D of 246M is 33x revenue (7.5M TTM) - pure clinical-stage bet with no commercial validation[Research and Development TTM]

Watch Triggers

  • Cash and Equivalents: Falls below 100MTriggers emergency financing at unfavorable terms or forced partnership
  • Issuance of Capital Stock: Exceeds 50M in single quarterSignals aggressive dilution; watch for >10% share count increase
  • Research and Development TTM: Drops >20% sequentiallyMay indicate pipeline prioritization or cash preservation mode

Bull Case

Near-zero debt (0.001 D/E) and 344M equity provides clean balance sheet for partnership deals or acquisition premium

Debt to EquityCommon Stockholders Equity

5.9B market cap on 7.5M revenue implies market sees high probability of clinical success in CNS pipeline

Market Cap TTMTotal Revenue TTMP/S Ratio

Bear Case

8-month cash runway at current burn forces near-term dilution or distressed deal regardless of pipeline progress

Cash and EquivalentsFree Cash Flow TTM

792x P/S assumes near-perfect execution - any clinical setback creates 80%+ downside to industry median valuation

P/S RatioTotal Revenue TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
30%

Leverage PRAX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Equity dilution or partnership deal likely within 12 months given cash runway constraints

3-12mhigh
  • 150M cash vs 229M annual burn rate
  • 6M raised recently signals ongoing capital needs
  • Zero debt capacity with minimal assets
FCF TTM: -229MCash: 150MIssuance of Capital Stock: 6M

Valuation Context

Caveats

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.